Comparison of ovarian response in the same women with the same or different lots of human menopausal gonadotropin

A variation in the bioactivity of different production lots of human menopausal gonadotropin (hMG) has been suggested. Therefore, we evaluated ovarian response to hMG in 14 women during three separate IVF cycles. The first two cycles were performed with the same lot (-03310027; Cycles A1 and A2); the third cycle utilized different lots of hMG (Cycle B). In all cycles, hMG was administered 3 ampules/day beginning cycle Day 3 and continued for at least 6 days. Estradiol and ultrasound evaluations were performed on Day 3, and then daily, beginning on cycle Day 8. Fourteen women completed all three cycles. There were no significant differences in baseline estradiol and ultrasound. Estradiol levels on Day 8 (A1, 754 ± 130; A2, 700 ± 107; B, 520 ± 80 pg/ml, analysis of variance p > 0.5) and on Day 9 (A1, 1051 ±144; A2, 1140 ± 155; B, 840 ± 124 pg/ml, p > 0.05) were similar as well. The number of small (1.0-1.4 cm) follicles, large (± 1.5 cm) follicles, and total follicles (Day 8: total A1, 5.5 ± 0.9; A2, 4.0 ± 0.7; B, 4.5 ± 0.9, p > 0.05; Day 9: total A1, 6.7 ± 0.9; A2, 6.9 ± 0.8; B, 6.9 ± 0.9, p > 0.05) in all three cycles were also similar. There was no significant difference in the day of hCG administration (A1, 9.1 ± 0.2; A2, 9.0 ± 0.1; B, 9.2 ± 0.2) or the total number of ampules of hMG utilized on Day 9 (A1, 1.1 ± 0.4; A2, 0.6 ± 0.2; B, 0.8 ±0.2). This study extends our previous observations in ovulatory women that ovarian response to hMG induction of superovulation is similar in successive cycles and demonstrates in vivo consistency of human ovarian response to different lots of Pergonal±